DOCSLIB.ORG

Enhancement of Hepatocarcinogenesis in Female Rats by Ethinyl Estradici and Mestranol but Not Estradici1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Enhancement of Hepatocarcinogenesis in Female Rats by Ethinyl Estradici and Mestranol but Not Estradici1 [CANCER RESEARCH 44, 3862-3869, September 1984] Enhancement of Hepatocarcinogenesis in Female Rats by Ethinyl Estradici and Mestranol but not Estradici1 James D. Yager,2 Harold A. Campbell, Daniel S. Longnecker, B. D. Roebuck, and Mary C. Benoit Departments ölAnatomy [J. D. Y.¡,Pathology [D. S. L], Pharmacology and Toxicology [B. D. R.¡,and Medicine [M. C. B.], Dartmouth Medical School, Hanover, New Hampshire 03756, and McArdle Laboratory tor Cancer Research, University of Wisconsin Medical School, Madison, Wisconsin 53706 [H. A. C.] ABSTRACT In experimental studies in animals, results have been obtained which suggest that synthetic estrogen treatment following car The effect of dietary exposure to synthetic estrogens on cinogen exposure (initiation) can enhance hepatic neoplasia. hepatocarcinogenesis was evaluated. Diethylnitrosamine-initi- Taper (32) was the first investigator to demonstrate that 2 ated and 0.85% NaCI solution-treated noninitiated female synthetic steroids used in oral contraceptive preparations in Sprague-Dawley rats were transferred to semisynthetic diets Europe, estradiol 17-phenylpropionate and estradiol benzoate, containing mestranol (0, 0.1, or 0.5 ppm), ethinyl estradiol (0.5 enhanced hepatocarcinogenesis in castrated female rats previ ppm), estradiol (0.6 ppm), or mestranol plus 0-methasone (0.5 ously initiated with A/-nitrosomorpholine In the United States, 2 and 0.2 ppm, respectively). 7-Glutamyl transferase (GGT>posi- synthetic estrogens, mestranol (170-ethinyl estradiol 3-methyl tive transections and hematoxylin and eosin-detectable nodules ether) and EE, are widely used in oral contraceptive preparations. and carcinomas were scored at 9 and 12 months. Quantitative We reported that, in intact, DEN-initiatedfemale Sprague-Dawley stereological calculations were performed to determine GGT rats, mestranol alone and together with norethynodrel enhanced lesion number and size. At 9 months, in diethylnitrosamine- the appearance of GGT-positive, presumptive preneoplastic foci initiated rats, ethinyl estradiol and mestranol caused 3.5- and (39, 40, 43). The data of Vesselinovitch and Mihailovich (33) 4.4-fold increases, respectively, in the number of GGT lesions demonstrated that mestranol enhanced the incidence and mul per liver and an increased incidence of hepatocellular carcinomas tiplicity of benign liver tumors in DEN-initiated female C57BL/6 while estradiol had no enhancing effect. Addition of /S-methasone x C3H Fi mice. Cameron et al. (3, 4) reported that EE enhanced to the mestranol-containing diet caused a significant decrease in the appearance of GGT foci and hyperplastic nodules in DEN- GGT lesion number but not carcinoma incidence compared to initiated male Fischer 344 rats. Wanless and Mediine (34) also mestranol alone. At 12 months, in diethylnitrosamine-initiated reported that EE enhanced the appearance of grossly visible rats, mestranol caused a dose-dependent increase in GGT lesion hyperplastic nodules and microscopic hyperplastic foci in male number. The hepatocellular carcinoma incidence was signifi Fischer 344 rats. They indicated that some of the grossly visible cantly increased at the high mestranol dose. Small increases in nodules were well-differentiated HCs but did not report the the numbers of larger GGT lesions were also observed in non- incidence of these neoplasms. initiated animals treated with mestranol and ethinyl estradiol and In 5 (3, 4, 32-34) of the studies mentioned above, initiation are most probably due to promotion of spontaneously initiated preceded treatment with the synthetic estrogens by a period hepatocytes. These results indicated that the synthetic estro ranging from 1 to 4 weeks. This suggests that the enhancement gens cause dramatic increases in the number of presumptive of hepatocarcinogenesis caused by the synthetic estrogens is preneoplastic GGT lesions. Carcinoma incidence is also en due to promotion (Refs. 34 and 38; see "Discussion"). However, hanced. Thus, these results confirm and extend our previous to date, for mestranol and EE, no studies have been reported studies which together with the results of others have shown where their enhancing activities have been directly compared, that synthetic estrogens can act as promoters of hepatocarci where dose-response effects were analyzed, and where HC nogenesis. incidence was definitively determined. The present report de scribes the results of studies designed to address these issues. INTRODUCTION In addition, since corticosteroids are growth inhibitory for liver (9, 18), the effect of addition of ¿3-methasonetoa mestranol- In humans,the evidencethat useof oralcontraceptivesteroids containing diet was also determined. Two- and 3-dimensional is associated with an increased incidence of benign liver neo analyses of GGT lesion number and size were performed as well plasms is strong (see Refs. 36, 39, 40, and 43). While the results as the histopathological evaluation of advanced lesions. The of several studies have also suggested an increased incidence of HC3 in women following prolonged use of these agents (11, results clearly show the strong enhancing ability of EE and 2 doses of mestranol but not estradiol on GGT lesion number and 15, 19), the strength of this association remains controversial HC incidence. (11,14) and deserves continued study. ' Supported by USPHS Grant CA32916/CA36701 from the National Cancer MATERIALS AND METHODS Institute. 2 To whom requests for reprints should be addressed. Animal Treatment. Female Sprague-Dawley rats (Charles River 'The abbreviations used are: HC, hepatocellular carcinoma; DEN, diethylnitro- Breeding Laboratories, Inc., Wilmington, MA) obtained in 2 groups were samine; GGT, -»-glutamyltransferase; M(L), mestranol, tow dose; M(H), mestranol, housed individually in wire-bottomed cages under controlled conditions high dose; EE, 17ß-ethinylestradiol; H & E, hematoxylin and eosin; PB, phénobar of temperature, humidity, and lighting. The 12-month experiment was bital; TCDD, 2,3,7,8-tetrachtorodibenzo-p-dioxin; SAL animals, animals given 0.85% NaCI solution. started 2 weeks prior to the 9-month experiment. Food and distilled Received March 8, 1984; accepted June 12, 1984. water were available ad libitum. Upon arrival, the animals were fed a 3862 CANCER RESEARCH VOL. 44 Downloaded from cancerres.aacrjournals.org on September 28, 2021. © 1984 American Association for Cancer Research. Promotion by Synthetic Estrogens defined semisynthetic basal control diet (43) obtained from Teklad (Mad Campbell er al. (5). The smallest size class has been designated Size ison, Wl). At approximately 7 weeks of age, the rats were subjected to Class 1, and the smallest lesion transectton reproducibly definable within a surgical two-thirds partial hepatectomy; 24 hr later, they were given this size class had a diameter of 50 /im. The size classes are defined by i.p. injections of either 0.85% NaCI solution (noninitiated, -DEN groups) a tog scale of maximum diameters u/m) by the series: Size Class 1, or DEN at 20 mg/kg body weight (initiated, +DEN groups). Twenty-four antilog 1.8; Size Class 2, antitog 1.9; Size Class 3, antilog 2.0 ... Size hr later, the animals were transferred (indicated by -»)to the various Class 20, antilog 3.7, as originally described by Campbell er al. (5). In treatment groups shown in Table 1. this size classification system, lesions in each subsequent size class The estrogens (Sigma Chemical Co., St. Louis, MO) were added to have a volume 2 times greater than those in the previous size class, the basal diet as described previously (43), and the diet was subsequently thus reflecting the increased tumor burden to the rat. The stereological fed in powder form. Mestranei was fed at 2 dose levels with the low calculations were not corrected for potential artifacts due to stretching dose [M(L)] being 0.1 ppm and the high dose [M(H)J being 0.5 ppm and shrinkage. The GGT lesion transections were essentially circular, which represents approximately 3 and 15 times the human dose, re thus representing essentially spherical growths. There was no evidence spectively. On the tow-dose diet, rats ingested approximately 6 ng of distortion in an elliptical fashion as a result of the histotogical proce mestranol/kg/day; at the high dose, they ingested 30 j/g mestranol/kg/ dure. day. The concentration of ethinyl estradici was 0.5 ppm, and that of Statistical Analyses of the Data. The data were subjected to a one estradici was 0.6 ppm. In one treatment group, animals were fed diet way analysis of variance with multiple comparisons among groups per containing M(H) plus ..i-methasone. Initially, this synthetic corticosteroid formed using the Neuman-Keuls procedure (2). Results reported as was also present at 0.5 ppm, but the animals failed to gain weight and significant using this procedure are less than the 5% level of significance. suffered hair toss. After 2 weeks, the dose of .-i-methasone was reduced In addition, in selected instances, 2 groups were compared using a 2- to 0.2 ppm, and it remained at that level for the duration of the experi tailed r test. Nodule and HC incidence data were analyzed using the \- ment. Food consumption and body weight data were obtained through test. out the course of the experiment. Histochemical and Histopathological Analyses. At the time of kill, RESULTS the livers were removed and weighed, and a liver sample from 2 of the Effects of Treatment on Animal Growth. Chart 1 showsthe remaining 4 lobes was obtained by the use of a 15-mm diameter cork borer. This procedure4 provides samples of similar size from each tobe body weight curves for the various groups of animals. In the 9- and each rat. The liver samples were frozen on dry ice and processed for GGT histochemistry as described previously (43) to reveal the pres ence of putative preneoplastic and neoplastic lesions. The GGT lesions —Bral•oc»-» RIMaS* detected consisted of foci and more advanced nodules and carcinomas. »- — ADEN—M No attempt was made to histopathologically identify and evaluate the 500400300200100öS«osti—E* DEN •EvSH— GGT lesions in H & E-stained serial sections.
Load more

Recommended publications
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • Supplementary Tables, Figures and Other Documents
    Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management in a Cohort of 135 Patients David Niedrig1,2, Ali Rahmany1,3, Kai Heib4, Karl-Dietrich Hatz4, Katja Ludin5, Andrea M. Burden3, Markus Béchir6, Andreas Serra7, Stefan Russmann1,3,7,* 1 drugsafety.ch; Zurich, Switzerland 2 Hospital Pharmacy, Clinic Hirslanden Zurich; Zurich Switzerland 3 Swiss Federal Institute of Technology Zurich (ETHZ); Zurich, Switzerland 4 INTLAB AG; Uetikon am See, Switzerland 5 Labor Risch, Molecular Genetics; Berne, Switzerland 6 Center for Internal Medicine, Clinic Hirslanden Aarau; Aarau, Switzerland 7 Institute of Internal Medicine and Nephrology, Clinic Hirslanden Zurich; Zurich, Switzerland * Correspondence: [email protected]; Tel.: +41 (0)44 221 1003 Supplementary Tables, Figures and Other Documents Figure S1: Example of credit-card sized pharmacogenomic profile issued to patients 1 Table S2: SNPs analyzed by the 16-gene panel test Gene Allele rs number ABCB1 Haplotypes 1236-2677- rs1045642 ABCB1 3435 rs1128503 ABCB1 rs2032582 COMT Haplotypes 6269-4633- rs4633 COMT 4818-4680 rs4680 COMT rs4818 COMT rs6269 CYP1A2 *1C rs2069514 CYP1A2 *1F rs762551 CYP1A2 *1K rs12720461 CYP1A2 *7 rs56107638 CYP1A2 *11 rs72547513 CYP2B6 *6 rs3745274 CYP2B6 *18 rs28399499 CYP2C19 *2 rs4244285 CYP2C19 *3 rs4986893 CYP2C19 *4 rs28399504 CYP2C19 *5 rs56337013 CYP2C19 *6 rs72552267 CYP2C19 *7 rs72558186 CYP2C19 *8 rs41291556 CYP2C19 *17 rs12248560 CYP2C9 *2 rs1799853 CYP2C9 *3 rs1057910 CYP2C9 *4 rs56165452 CYP2C9 *5 rs28371686 CYP2C9 *6 rs9332131 CYP2C9
    [Show full text]
  • A Pharmaceutical Product for Hormone Replacement Therapy Comprising Tibolone Or a Derivative Thereof and Estradiol Or a Derivative Thereof
    Europäisches Patentamt *EP001522306A1* (19) European Patent Office Office européen des brevets (11) EP 1 522 306 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: A61K 31/567, A61K 31/565, 13.04.2005 Bulletin 2005/15 A61P 15/12 (21) Application number: 03103726.0 (22) Date of filing: 08.10.2003 (84) Designated Contracting States: • Perez, Francisco AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 08970 Sant Joan Despi (Barcelona) (ES) HU IE IT LI LU MC NL PT RO SE SI SK TR • Banado M., Carlos Designated Extension States: 28033 Madrid (ES) AL LT LV MK (74) Representative: Markvardsen, Peter et al (71) Applicant: Liconsa, Liberacion Controlada de Markvardsen Patents, Sustancias Activas, S.A. Patent Department, 08028 Barcelona (ES) P.O. Box 114, Favrholmvaenget 40 (72) Inventors: 3400 Hilleroed (DK) • Palacios, Santiago 28001 Madrid (ES) (54) A pharmaceutical product for hormone replacement therapy comprising tibolone or a derivative thereof and estradiol or a derivative thereof (57) A pharmaceutical product comprising an effec- arate or sequential use in a method for hormone re- tive amount of tibolone or derivative thereof, an effective placement therapy or prevention of hypoestrogenism amount of estradiol or derivative thereof and a pharma- associated clinical symptoms in a human person, in par- ceutically acceptable carrier, wherein the product is pro- ticular wherein the human is a postmenopausal woman. vided as a combined preparation for simultaneous, sep- EP 1 522 306 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 1 522 306 A1 2 Description [0008] The review article of Journal of Steroid Bio- chemistry and Molecular Biology (2001), 76(1-5), FIELD OF THE INVENTION: 231-238 provides a review of some of these compara- tive studies.
    [Show full text]
  • Effects of Diethylstilbestrol, Norethindrone, and Mestranol on Selected Microbes
    Loyola University Chicago Loyola eCommons Master's Theses Theses and Dissertations 1974 Effects of Diethylstilbestrol, Norethindrone, and Mestranol on Selected Microbes John N. Haan Loyola University Chicago Follow this and additional works at: https://ecommons.luc.edu/luc_theses Part of the Physiology Commons Recommended Citation Haan, John N., "Effects of Diethylstilbestrol, Norethindrone, and Mestranol on Selected Microbes" (1974). Master's Theses. 2756. https://ecommons.luc.edu/luc_theses/2756 This Thesis is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Master's Theses by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. Copyright © 1974 John N. Haan EFFECTS OF DIETHYLSTILBESTROL, NORETHINDRONE, AND MESTRANOL ON SELECTED MICROBES by John N. Haan A Thesis Submitted to the Faculty of the Graduate School of Loyola University of Chicago in Partial Fulfillment of the Requirements for the Degree of Master of Science November 1974 TABLE OF CONTENTS ,.' I. Introduction and Review of the Literature ................... 1 'II. Materials and Methods....................................... 7 III. Results· ..................................................... 13 A. Effects of Ethanol on the Microbes Studied .............. 13 1. Growth Studies ...................................... 13 B. Effects of Norethindrone
    [Show full text]
  • Table E-46. Therapies Used in Trials Comparing Hormone with Placebo Ar Est Study N Rxcat Dose Route Generic Trade M Dose Martin 1971 1 56 Plac Oral
    Table E-46. Therapies used in trials comparing hormone with placebo Ar Est Study N RxCat Dose Route Generic Trade m Dose Martin 1971 1 56 Plac Oral Standar 2 53 EP seq 0.025 mg E + 1 mg P Oral mestranol + norethindrone d 3 56 EP seq 0.05 mg E + 1 mg P Oral mestranol + norethindrone High Campbell 1 68 Plac Oral 1977 2 68 Est 1.25 mg Oral conjugated equine estrogens Premarin High Baumgardner 1 42 Plac Oral 1978 2 42 Est 0.1 mg Oral quinestrol Estrovis Low Standar 3 35 Est 0.2 mg Oral quinestrol Estrovis d 4 37 Est 1.25 mg Oral conjugated estrogen Premarin High E-65 Ar Est Study N RxCat Dose Route Generic Trade m Dose Coope 1981 1 26 Plac Oral UltraLo 2 29 Est 0.3mg Oral piperazine estrone sulphate w Jensen 1983 1 90 Plac Oral estradiol + estriol + 2 41 EP seq 4 mg E + 1 mg P Oral Trisequens Forte High norethisterone acetate Foidart 1991 1 53 Plac VagPes Ortho-Gynest- 2 56 Est 1 mg VagPes estriol Low Depot Eriksen 1992 1 79 Plac VagTab 2 75 Est 0.025 mg VagTab estradiol Vagifem Low Wiklund 1993 11 1 Plac Patch 1 11 Standar 2 Est 0.05 mg Patch estradiol 2 d Derman 1995 1 42 Plac Oral Standar 2 40 EP seq 2 mg E + 1 mg P Oral estradiol + norethindrone acetate Trisequens d Saletu 1995 1 32 Plac Patch Standar 2 32 Est 0.05 mg Patch estradiol Estraderm d Good 1996 1 91 Plac Patch Standar 2 88 Est 0.05 mg Patch estradiol Alora d 3 94 Est 0.10 mg Patch estradiol Alora High Speroff (Study 1) 1 54 Plac Patch 1996 UltraLo 2 54 Est 0.02 mg Patch estradiol FemPatch w E-66 Ar Est Study N RxCat Dose Route Generic Trade m Dose Chung 1996 1 40 Plac Oral Standar
    [Show full text]
  • Estrogen, Progesterone and Contraceptives
    Estrogen, Progesterone and Contraceptives BY: DR MEHERUNISA CIMS ASSOCIATE PROFESSOR ESTROGEN Actions • Female reproductive system: 1. Growth and development • CNS: 1. Feedback inhibition of gonadotropin (LH/FSH) secretion. 2. stimulation of CTZ to cause nausea and vomiting. • BLOOD: 1. Increased predisposition to deep vein thrombosis and pulmonary embolism due to increased synthesis of factor VII, VIII, IX and X and decreased production of antithrombin III by the liver. 2. Favourable effect on lipid profile by decreasing LDL and increasing HDL. ESTROGEN • METABOLIC 1. Glucose intolerance 2. Sodium and water retention. 3. Maintain bone mass by decreasing the bone resorption. • Increased risk of gall bladder stones and cholestatic jaundice. • Can result in hepatic adenoma on prolonged use. • Vasodilation by increasing the production of NO. ESTROGEN PREPARATIONS • Natural steroidal estrogen ✓Estrone, Estradiol ( maximum), Estriol • Synthetic steroidal estrogen ✓Ethinyl estradil ✓Mestranol ✓Tibolone • Synthetic non steroidal estrogens ✓Diethylstilbesterol ✓Dienestrol Pharmacokinetics ✓Natural estrogens: orally inactive due to first pass metabolism ✓Synthetic estrogens: orally active ✓Estradiol is converted to estrone and estriol in liver/ peripheral tissue ✓Orally administered estrogen → absorbed from intestine→ enterohepatic circulation → high hepatic to peripheral ratio→ hepatic side effects Therapeutic uses • Oral contraceptive pills ( OCP) • Postmenopausal Hormone Replacement Therapy ( HRT) • No progesterone/estrogen production after
    [Show full text]
  • Combined Hormonal Contraceptive Use Among Breastfeeding Women: an Updated Systematic Review☆,☆☆ ⁎ Naomi K
    Contraception 94 (2016) 262–274 Review article Combined hormonal contraceptive use among breastfeeding women: an updated systematic review☆,☆☆ ⁎ Naomi K. Teppera, , Sharon J. Phillipsb, Nathalie Kappb,c, Mary E. Gaffieldb, Kathryn M. Curtisa aDivision of Reproductive Health, US Centers for Disease Control and Prevention, Atlanta, GA 30341 bDepartment of Reproductive Health and Research, World Health Organization, Geneva, Switzerland (prior affiliation for Dr. Phillips and Dr. Kapp) cCurrent affiliation: Independent reproductive health consultant, Paris, France Received 27 March 2015; revised 13 May 2015; accepted 13 May 2015 Abstract Background: Contraception is important for women who are postpartum, including those who are breastfeeding. Use of combined hormonal contraceptives (CHCs) may affect breastfeeding performance and infant health outcomes. Objective: The objective was to identify evidence examining clinical outcomes for breastfeeding and infant health among breastfeeding women using CHCs compared to nonusers. Search strategy: We searched the PubMed database for all articles published from database inception through September 30, 2014. Selection criteria: We included primary research studies that compared breastfeeding women using CHCs with breastfeeding women using nonhormonal or no contraception, or compared breastfeeding women initiating combined hormonal contraception at early versus later times postpartum. Breastfeeding outcomes of interest included duration, rate of exclusive breastfeeding and timing of supplementation.
    [Show full text]
  • For Selected Potent Endocrine Disrupting Steroids: Development and Application to Environmental Studies
    Rapid and Sensitive Enzyme-Linked Immunosorbent Assays (ELISAs) for Selected Potent Endocrine Disrupting Steroids: Development and Application to Environmental Studies Chatchaporn Uraipong Thesis submitted in partial fulfillment of the requirement for the Degree of Master of Science (Research) School of Chemical Engineering The University of New South Wales September, 2010 ABSTRACT Endocrine disrupting chemicals (EDCs) are chemicals that alter functions of the endocrine system and cause health effects in an intact organism, or progeny, or population, with reproductive, developmental, or carcinogenic consequences. In order to facilitate risk assessment of potential endocrine disrupting steroids that are present in ultra low concentrations in the Australian environment, there is a need to boost the analytical capacity for EDC detection. One strategy is to develop antibody-based techniques that can offer simple, cost-effective and reliable analysis with high throughput capacity and portability for real-time monitoring. This thesis describes the design and synthesis of hapten molecules, raising of specific antibodies, formatting and characterising of a series of sensitive competitive Enzyme-Linked Immunosorbent Assays (ELISAs) for 17β-estradiol (E2), 17α-ethynylestradiol (EE2), ethylestradiol-3-methyl ether (mestranol) and testosterone (T), including validation of their performance as fast and effective water monitoring tools. Application of the developed assays to investigate the levels of the target EDCs in bodies of water and efficiency of water treatment plants in urban and rural areas in New South Wales, Australia, is also discussed. 17α-Ethynylestradiol and related synthetic estrogens, are active ingredients of contraceptive pills and hormone therapy, and have been identified as potent EDCs (Warner and Jenkins, 2007).
    [Show full text]
  • Steroidal Estrogens
    FINAL Report on Carcinogens Background Document for Steroidal Estrogens December 13 - 14, 2000 Meeting of the NTP Board of Scientific Counselors Report on Carcinogens Subcommittee Prepared for the: U.S. Department of Health and Human Services Public Health Service National Toxicology Program Research Triangle Park, NC 27709 Prepared by: Technology Planning and Management Corporation Canterbury Hall, Suite 310 4815 Emperor Blvd Durham, NC 27703 Contract Number N01-ES-85421 Dec. 2000 RoC Background Document for Steroidal Estrogens Do not quote or cite Criteria for Listing Agents, Substances or Mixtures in the Report on Carcinogens U.S. Department of Health and Human Services National Toxicology Program Known to be Human Carcinogens: There is sufficient evidence of carcinogenicity from studies in humans, which indicates a causal relationship between exposure to the agent, substance or mixture and human cancer. Reasonably Anticipated to be Human Carcinogens: There is limited evidence of carcinogenicity from studies in humans which indicates that causal interpretation is credible but that alternative explanations such as chance, bias or confounding factors could not adequately be excluded; or There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors: (1) in multiple species, or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site or type of tumor or age at onset; or There is less than sufficient evidence of carcinogenicity in humans or laboratory animals, however; the agent, substance or mixture belongs to a well defined, structurally-related class of substances whose members are listed in a previous Report on Carcinogens as either a known to be human carcinogen, or reasonably anticipated to be human carcinogen or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.
    [Show full text]
  • Supplemental Figure
    ● Agonist ● Antagonist ● Interference AR AUC 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 17beta−Trenbolone 5alpha−Dihydrotestosterone 17−Methyltestosterone Testosterone propionate Norethindrone Norgestrel GSK232420A 4−Androstene−3,17−dione Progesterone 17beta−Estradiol Mifepristone 17alpha−Ethinylestradiol Hydroxyflutamide 17alpha−Hydroxyprogesterone Corticosterone Nilutamide Basic Blue 7 Triphenyltin hydroxide Bicalutamide Tributyltin benzoate 17alpha−Estradiol Gentian Violet Equilin Zinc pyrithione Triticonazole Fenitrothion Mestranol Tributyltin methacrylate 2,2−Bis(4−hydroxyphenyl)−1,1,1 Dibutyltin dichloride Flutamide Methyltrioctylammonium chlorid Rhodamine 6G Tributyltetradecylphosphonium Emamectin benzoate Phenylmercuric acetate Cyproterone acetate Chlorothalonil 9−Phenanthrol 2,2',4,4'−Tetrahydroxybenzophe Melengestrol acetate Dehydroepiandrosterone 1−Chloro−2,4−dinitrobenzene SSR240612 Methylbenzethonium chloride Vinclozolin Tetraconazole Ziram Didecyldimethylammonium chlori Econazole nitrate Myristyltrimethylammonium chlo Clorophene Abamectin Octyl gallate 2−Chloro−4−phenylphenol Bisphenol A Propanil Dexamethasone sodium phosphate meso−Hexestrol Dichlorophen Hydroxyprogesterone caproate SSR241586 Bisphenol AF Prednisone Dichlone Reserpine Chlorobenzilate Diethylstilbestrol 3−Hydroxyfluorene Procymidone 4−Cumylphenol 4−Hydroxytamoxifen Napropamide PharmaGSID_48519 Clomiphene citrate (1:1) Chlorhexidine diacetate Tebuconazole Imazalil Dinocap PharmaGSID_48513 Linuron Prochloraz Zoxamide TDCPP Captan 3,3'−Dimethoxybenzidine dihydr 4−Phenylphenol
    [Show full text]
  • Toxicological Summary for Mestranol (PDF)
    Health Based Guidance for Water Health Risk Assessment Unit, Environmental Health Division 651-201-4899 Web Publication Date: May 2016 Expiration Date: May 2021 Toxicological Summary for: Mestranol CAS: 72-33-3 Synonyms: 3-Methoxy-19-nor-17α-pregna-1,3,5(10)-trien-20-yn-17-ol; (17alpha)-3-Methoxy-19- norpregna-1,3,5(10)-trien-20-yn-17-ol; Ethinylestradiol 3-methyl ether; 17alpha- Ethinylestradiol 3-methyl ether, EEME, MeEE Mestranol (MeEE) is the 3-methyl ether of 17α-ethinylestradiol (EE2). MeEE is not initially biologically active as a contraceptive hormone but it is rapidly demethylated in the liver to form the biologically active EE2. A dose of 50 µg of MeEE is considered to be bioequivalent to 35 µg of EE2 as a result of a 70% conversion efficiency in the liver (e.g., 35 µg/0.70 = 50 µg) (Brody et al. 1989). The relative bioequivalence is the basis for the different contraceptive dose levels for MeEE and EE2 used to achieve the same effect in adult humans. HBVs are available for 17α-ethinylestradiol (EE2). The Minnesota Department of Health (MDH) recommends adjusting the reference doses (RfDs) derived for EE2 by a factor of 0.7 to account for relative bioequivalence and then deriving Risk Assessment Advice (RAAs) for MeEE based on the adjusted RfDs. The following are MeEE RfDs, based on RfDs for EE2 adjusted for relative bioequivalence according to the following equation: RfDMeEE = RfDEE2/0.7 Acute RfDMeEE = Not derived. Insufficient data. -7 -7 Short-term RfDMeEE = Short-term RfDEE2/0.7 = 1.7 x 10 /0.7 = 2.4 x 10 mg/kg-d -8 -8 Subchronic RfDMeEE = Subchronic RfDEE2/0.7 = 1.4 x 10 /0.7 = 2.0 x 10 mg/kg-d -8 -8 Chronic RfDMeEE = Chronic RfDEE2/0.7 = 1.4 x 10 /0.7 = 2.0 x 10 mg/kg-d The following recommendation represents Risk Assessment Advice (RAA) for mestranol using adjusted RfDs and the same duration-based algorithms applied to derive 17α-ethinylestradiol HBVs: Acute nRAAMeEE = Not derived.
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]